Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and delivery of immune-based therapies for patients around the world. Zenas is rapidly advancing a deep portfolio of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com.
Location: United States, Massachusetts, Waltham
Employees: 11-50
Total raised: $318M
Investors 2
| Date | Name | Website |
| 21.11.2022 | Vivo Capit... | vivocapita... |
| 17.11.2022 | Longitude ... | longitudec... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.05.2024 | Series C | $200M | - |
| 11.11.2022 | Series B | $118M | Enavate Sc... |
Mentions in press and media 11
| Date | Title | Description |
| 09.10.2025 | China’s InnoCare Tumbles After Licensing Three Novel Drugs to US Peer Zenas | (Yicai) Oct. 9 -- InnoCare Pharma’s share price skidded after the Beijing-based company licensed three innovative drugs to US firm Zenas BioPharma in a deal worth more than USD2 billion. InnoCare [SHA: 688428] closed 6.3 percent lower at CN... |
| 10.05.2024 | Zenas BioPharma Secures Impressive $200 Million in Series C Funding to Propel Immunology-Focused Clinical Development Programs | Zenas BioPharma, a renowned global biopharmaceutical company based in Waltham, Massachusetts, recently announced the successful closure of an upsized $200 million Series C financing round. This significant funding was led by esteemed invest... |
| 09.05.2024 | US-based Zenas BioPharma closes upsized Series C round at $200m | Massachusetts, US-based clinical-stage biopharmaceutical firm Zenas BioPharma has closed an upsized $200-million Series C round of financing to advance mid- and late-stage immunology-focused clinical development programmes. |
| 09.05.2024 | Zenas BioPharma Raises $200M in Series C Financing | Zenas BioPharma, a Waltham, MA-based biopharmaceutical company developing inflammation and immunology-directed therapies, raised $200M in Series C funding. The round was led by SR One, NEA, Norwest Venture Partners, and Delos Capital with p... |
| 07.05.2024 | Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs | Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and other new and existing investors Proceeds to support ongoing mid- to late-stage clinical ... |
| 07.05.2024 | Zenas adds $200M series C to reach a bucket of key readouts for lead monoclonal antibody | Zenas BioPharma has bagged a $200 million series C, extending its cash runway another 18 months through a raft of key readouts for its lead monoclonal antibody obexelimab. The new financing—Zenas’ second consecutive nine-digit haul—was led ... |
| 05.09.2023 | Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb | - |
| 11.11.2022 | Autoimmune Biotech Zenas Gets $118M to Take Antibody Drug Into Phase 3 | Zenas BioPharma is preparing to take its lead drug candidate into a global Phase 3 test and it now has $118 million to finance the clinical research. The Zenas drug, obexelimab, is being developed as a treatment for IgG4-RD, a chronic infla... |
| 10.11.2022 | Zenas BioPharma raises $118m Series B round to advance pipeline | US-based Zenas BioPharma, an immune therapy developer with operations in China, has secured $118 million in a Series B round of financing to advance its pipeline products. The biopharma firm, which is developing ZB001 in China for the treat... |
| 08.11.2022 | Zenas BioPharma Raises $118M in Series B Funding | Zenas BioPharma, a Waltham, MA-based biopharmaceutical company, raised $118M in Series B funding. The round was led by Enavate Sciences, with participation from Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Age... |
Show more